Laboratory investigation of primary aldosteronism.
Authors:
- Michael StowasserMSMichael Stowasser
- Paul J TaylorPTPaul J Taylor
- Eduardo PimentaEPEduardo Pimenta
- Ashraf H Al-Asaly AhmedAAAshraf H Al-Asaly Ahmed
- Richard D GordonRGRichard D Gordon
- 1 May 2010
- journal article
- Vol. 31 (2) , 39-56
Abstract
Availability and wider application of the plasma aldosterone/renin ratio (ARR) as a screening test for primary aldosteronism (PA) has led to the recognition that PA is the most common potentially curable and specifically treatable form of hypertension, possibly accounting for as many as 5-13% of patients. Aldosterone excess also has adverse cardiovascular consequences that go above and beyond hypertension development. These findings support the concept that PA plays an important role in cardiovascular disease states and should be systematically sought and specifically treated, and have led to the development of a US Endocrine Society clinical guideline for the detection, diagnosis and management of this condition. Reliable detection requires that interfering factors (including medications known to alter the ratio) are controlled before ARR measurement (or their effects taken into account), and reliable methods such as fludrocortisone suppression testing are used to confirm PA. Because computed tomography frequently misses aldosterone-producing adenomas yet demonstrates non-functioning nodules, adrenal venous sampling is the only dependable way to differentiate unilateral (surgically correctable) from bilateral (usually treated with aldosterone antagonist medications) forms of PA. For the glucocorticoid-remediable form of PA (familial hyperaldosteronism type I), genetic testing for the causative 'hybrid' 11beta-hydroxylase/aldosterone synthase gene has greatly facilitated detection. Laboratory assessment (including suppression testing post-operatively, and renin measurement during treatment with aldosterone antagonist medications) can assist in assessing therapeutic responses and in guiding ongoing management. Development of new, highly reliable high-throughput mass spectrometric methods for measuring aldosterone and renin should further enhance detection and reliability of diagnostic workup for PA.Keywords
This publication has 117 references indexed in Scilit:
- Heritable forms of hypertensionPediatric Nephrology, 2009
- Renal Damage in Primary AldosteronismHypertension, 2006
- Primary aldosteronism—careful investigation is essential and rewardingMolecular and Cellular Endocrinology, 2004
- Validity of the Aldosterone-Renin Ratio Used to Screen for Primary AldosteronismMayo Clinic Proceedings, 2001
- A New Genetic Test for Familial Hyperaldosteronism Type I Aids in the Detection of Curable HypertensionBiochemical and Biophysical Research Communications, 1995
- Myocardial scintigraphic characteristics in patients with primary aldosteronism.Hypertension, 1994
- Pseudohyperkalemia Caused by Fist Clenching during PhlebotomyNew England Journal of Medicine, 1990
- Dexamethasone-suppressible hyperaldosteronism. Adrenal transition cell hyperplasia?Hypertension, 1986
- Aldosterone-Producing-Adenoma (A-P-A): Effect of PregnancyClinical and Experimental Hypertension. Part A: Theory and Practice, 1982
- A diurnal rhythm in plasma renin activity in man.Journal of Clinical Investigation, 1966